Genzyme

About: Genzyme is a based out in . It is known for research contribution in the topics: Enzyme replacement therapy & Population. The organization has 3085 authors who have published 3472 publications receiving 177632 citations. The organization is also known as: Sanofi Genzyme.

Molecular order in mucolipidosis II and III nomenclature

Abstract: Sara S. Cathey,* Mariko Kudo, Stephan Tiede, Annick Raas-Rothschild, Thomas Braulke, Michael Beck, Harold A. Taylor, William M. Canfield, Jules G. Leroy, Elizabeth F. Neufeld, and Victor A. McKusick Greenwood Genetic Center, Greenwood, South Carolina Genzyme Corporation, Oklahoma City, Oklahoma Schleswig-Holstein University Hospital, Lübeck, Germany Department of Human Genetics, Hadassah Hebrew University Hospital, Jerusalem, Israel Department of Biochemistry, Children’s Hospital, University of Hamburg, Hamburg, Germany Children’s Hospital, University of Mainz, Mainz, Germany Department of Biological Chemistry, David Geffen School of Medicine at UCLA, Los Angeles, California McKusick-Nathans Institute of Genetic Medicine, The Johns Hopkins Hospital, Baltimore, Maryland

Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens

Abstract: Objective: To evaluate immune responses to neoantigen and recall antigens in healthy subjects treated with teriflunomide. Methods: This was a randomized, double-blind, placebo-controlled study. Subjects received oral teriflunomide (70 mg once daily for 5 days followed by 14 mg once daily for 25 days) or placebo for 30 days. Antibody responses were evaluated following rabies vaccination (neoantigen) applied at days 5, 12, and 31 of the treatment period. Occurrence of delayed-type hypersensitivity (DTH) to Candida albicans, Trichophyton, and tuberculin (recall antigens) was assessed before and at the end of treatment to investigate cellular memory response. Safety and pharmacokinetics were evaluated. Results: Forty-six randomized subjects were treated (teriflunomide, n 5 23; placebo, n 5 23) and completed the rabies vaccination. Geometric mean titers for rabies antibodies were lower with teriflunomide at days 31 and 38 than with placebo. However, all subjects achieved sufficient seroprotection following rabies vaccination (titers well above the 0.5 IU/mL threshold). Overall, the DTH response to recall antigens in the teriflunomide group did not notably differ from responses in the placebo group. Conclusions: Following vaccination, geometric mean titers for rabies antibodies were lower with teriflunomide than with placebo. However, teriflunomide did not limit the ability to achieve seroprotective titers against this neoantigen. Evaluation of DTH showed that teriflunomide had no adverse impact on the cellular memory response to recall antigens.